LLY

888.16

-1.49%↓

JNJ

242.08

+0.61%↑

ABBV

210.85

+0.43%↑

NVS

149.23

-0.83%↓

MRK

120.47

+0.79%↑

LLY

888.16

-1.49%↓

JNJ

242.08

+0.61%↑

ABBV

210.85

+0.43%↑

NVS

149.23

-0.83%↓

MRK

120.47

+0.79%↑

LLY

888.16

-1.49%↓

JNJ

242.08

+0.61%↑

ABBV

210.85

+0.43%↑

NVS

149.23

-0.83%↓

MRK

120.47

+0.79%↑

LLY

888.16

-1.49%↓

JNJ

242.08

+0.61%↑

ABBV

210.85

+0.43%↑

NVS

149.23

-0.83%↓

MRK

120.47

+0.79%↑

LLY

888.16

-1.49%↓

JNJ

242.08

+0.61%↑

ABBV

210.85

+0.43%↑

NVS

149.23

-0.83%↓

MRK

120.47

+0.79%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.13 2.48

Buy Sell

Overview

Share price change

24h

Current

Min

3.93

Max

4.2

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+264.02% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.7M 231M
Previous open	1.65
Previous close	4.13

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 mar 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar 2026, 23:36 UTC

Market Talk

Major News Events

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar 2026, 23:35 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar 2026, 23:29 UTC

Earnings

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar 2026, 23:28 UTC

Earnings

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar 2026, 23:27 UTC

Earnings

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar 2026, 23:04 UTC

Acquisitions, Mergers, Takeovers

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar 2026, 22:26 UTC

Earnings

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar 2026, 22:08 UTC

Earnings

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

26 mar 2026, 22:07 UTC

Market Talk

Major News Events

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar 2026, 22:00 UTC

Earnings

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

264.02% upside

12 Months Forecast

Average 14.67 USD 264.02%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.